A U.S. review panel on Friday recommended loosening restrictions on all but one of a buzzy class of peptides, dismissing protests from medical experts who say none are well studied enough to justify wide access.
If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.
If you want to read more Like this articles, you can visit our Science category.
